PMID- 34159558
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20211018
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 38
IP  - 7
DP  - 2021 Jul
TI  - Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A 
      Retrospective, Propensity Score-Matched, US Health Claims Analysis.
PG  - 4115-4129
LID - 10.1007/s12325-021-01818-3 [doi]
AB  - INTRODUCTION: Adalimumab and golimumab are subcutaneously administered anti-tumor 
      necrosis factor alpha (TNFalpha) biologics used in the treatment of ulcerative colitis 
      (UC). To date, no studies have directly compared treatment patterns and 
      healthcare resource utilization (HRU) among patients with UC receiving these 
      therapies in a real-world setting. The objective of this study was to compare 
      these outcomes among patients with UC treated with either adalimumab or golimumab 
      using a US claims database. METHODS: Patients with UC treated with golimumab or 
      adalimumab were identified using the US Optum Clinformatics((R)) Data Mart 
      database. Outcomes of interest included treatment patterns (discontinuations, 
      dose optimizations, persistence, and concomitant medication use) and HRU 
      (outpatient office visits, emergency room [ER] visits, and inpatient stays). 
      Propensity score matching (PSM) was used to account for differences in 
      confounding variables between groups. RESULTS: Overall, 990 patients were 
      identified (golimumab: n = 277; adalimumab: n = 713). After PSM, 246 patients 
      were included in each group. There were no significant differences between the 
      adalimumab and golimumab groups over the full follow-up period in terms of 
      treatment discontinuations (53.7% vs. 51.2%; P = 0.5881), dose optimizations 
      (35.4% vs. 39.4%; P = 0.3515), or persistence (338.2 vs. 361.2 days; P = 0.4194). 
      During the year after initiating therapy, there were no significant differences 
      in concomitant immunosuppressant (21.9% vs. 21.7%; P = 0.9686) or corticosteroid 
      use (74.7% vs. 78.8%; P = 0.3573) or in HRU outcomes including outpatient office 
      visits (93.3% vs. 94.0%; P = 0.7660), ER visits (15.2% vs. 10.9%; P = 0.2238), 
      and inpatient stays (15.2% vs. 13.6%; P = 0.6680). CONCLUSIONS: In this 
      nationwide PSM cohort study of patients with UC receiving golimumab or 
      adalimumab, no significant differences were observed between groups for treatment 
      patterns or HRU outcomes. High rates of concomitant corticosteroid use, treatment 
      discontinuations, and HRU while on therapy highlight key unmet needs in the 
      treatment of UC.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Healthcare Ltd., part 
      of Springer Nature.
FAU - Stewart, Michael J
AU  - Stewart MJ
AD  - Division of Digestive Care and Endoscopy, Department of Medicine, Dalhousie 
      University, Halifax, NS, Canada.
FAU - Bessissow, Talat
AU  - Bessissow T
AD  - Division of Gastroenterology, Montreal General Hospital, McGill University Health 
      Centre, Montreal, QC, Canada.
FAU - Gregor, James
AU  - Gregor J
AD  - Division of Gastroenterology, Department of Medicine, Western University, London, 
      ON, Canada.
FAU - Hazel, Maureen
AU  - Hazel M
AD  - Janssen Inc., 19 Green Belt Dr, Toronto, ON, M3C 1L9, Canada.
FAU - In, Tracy S H
AU  - In TSH
AD  - Janssen Inc., 19 Green Belt Dr, Toronto, ON, M3C 1L9, Canada.
FAU - Karra, Kinda
AU  - Karra K
AD  - Janssen Inc., 19 Green Belt Dr, Toronto, ON, M3C 1L9, Canada.
AD  - Merck Canada Inc., Kirkland, QC, Canada.
FAU - Dajnowiec, Dorota
AU  - Dajnowiec D
AD  - Janssen Inc., 19 Green Belt Dr, Toronto, ON, M3C 1L9, Canada.
AD  - Edwards Lifesciences Corp., Irvine, CA, USA.
FAU - Williamson, Martin
AU  - Williamson M
AD  - Janssen Inc., 19 Green Belt Dr, Toronto, ON, M3C 1L9, Canada.
FAU - Sattin, Bernie
AU  - Sattin B
AUID- ORCID: 0000-0002-4062-6716
AD  - Janssen Inc., 19 Green Belt Dr, Toronto, ON, M3C 1L9, Canada. 
      bsattin@its.jnj.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210622
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
MH  - Adalimumab/therapeutic use
MH  - Cohort Studies
MH  - *Colitis, Ulcerative/drug therapy
MH  - Humans
MH  - Infliximab
MH  - Insurance Claim Review
MH  - Propensity Score
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - *Tumor Necrosis Factor Inhibitors
OTO - NOTNLM
OT  - Adalimumab
OT  - Anti-TNFalpha biologics
OT  - Golimumab
OT  - Healthcare resource utilization
OT  - Propensity score matching
OT  - Real-world evidence
OT  - Treatment patterns
OT  - Ulcerative colitis
EDAT- 2021/06/24 06:00
MHDA- 2021/08/06 06:00
CRDT- 2021/06/23 07:32
PHST- 2021/04/21 00:00 [received]
PHST- 2021/06/05 00:00 [accepted]
PHST- 2021/06/24 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
PHST- 2021/06/23 07:32 [entrez]
AID - 10.1007/s12325-021-01818-3 [pii]
AID - 10.1007/s12325-021-01818-3 [doi]
PST - ppublish
SO  - Adv Ther. 2021 Jul;38(7):4115-4129. doi: 10.1007/s12325-021-01818-3. Epub 2021 
      Jun 22.